Cognitive functioning in children with pantothenate-kinase-associated neurodegeneration undergoing deep brain stimulation

Dev Med Child Neurol. 2011 Mar;53(3):275-9. doi: 10.1111/j.1469-8749.2010.03815.x. Epub 2010 Dec 17.

Abstract

Aim: To examine the cognitive functioning of young people with pantothenate-kinase-associated neurodegeneration (PKAN) after pallidal deep brain stimulation (DBS). PKAN is characterized by progressive generalized dystonia and has historically been associated with cognitive decline. With growing evidence that DBS can improve motor function in adults and children with PKAN, there is now the opportunity to study the cognitive profiles of these patients over time.

Method: We present a case series of seven children (mean age 11 y 7 mo, SD 3 y 2 mo) undergoing bilateral pallidal DBS for the management of severe PKAN-associated dystonia. We administered standardized measures of intellectual ability and memory where possible, before DBS and 1 to 4 years after DBS.

Results: No cognitive decline was observed and scores improved in all but one child (whose dystonia could not be adequately controlled owing to multiple medical problems). In line with a stabilization or reduction in their dystonia, all but one child was able to tolerate longer assessment sessions and complete either the same or a greater number of subtests.

Interpretation: These findings suggest that apparent cognitive impairments may reflect difficulties in accessing cognition owing to severity of dystonia. Intellectual decline previously associated with PKAN may have been overestimated.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Child
  • Cognition Disorders / etiology*
  • Cognition Disorders / metabolism
  • Cognition Disorders / therapy*
  • Cognition*
  • Deep Brain Stimulation*
  • Dystonia / etiology
  • Dystonia / therapy
  • Female
  • Globus Pallidus
  • Humans
  • Male
  • Neuropsychological Tests
  • Pantothenate Kinase-Associated Neurodegeneration / psychology*
  • Pantothenate Kinase-Associated Neurodegeneration / therapy*
  • Severity of Illness Index
  • Treatment Outcome